Eli Lilly and CompanyLLY

Pharmaceutical growth leader with 56% revenue growth from blockbuster GLP-1 drugs, 83% gross margin, and 35% 1Y return. Weighted at 11% as top non-tech growth story with exceptional ROE of 107%.